Jiangxi Jemincare Group has overseen the official launch and first prescription of its omalizumab biosimilar, CMAB007, a version of Roche/Genentech’s (SWX: ROG) anti-IgE dermatology and asthma therapy Xolair, in Beijing. The drug’s launch comes less than two months after it received market approval.
Therapeutic Applications of Omalizumab
Omalizumab is utilized to manage asthma and reduce the likelihood of acute asthma episodes with lower doses of inhaled corticosteroids. It serves as a treatment for immunoglobulin E (IgE)-mediated asthma, offering an alternative for patients who require targeted therapy for their conditions.
Development and Licensing of CMAB007
MabPharm Ltd (HKG: 2181) was responsible for developing the biosimilar version of omalizumab before licensing promotion rights to Jemincare in March 2023. The approval and subsequent launch of CMAB007 mark a significant milestone, as it represents the first home-grown therapeutic biologic for asthma to be made available in China, potentially increasing access to this crucial treatment for patients within the country.-Fineline Info & Tech
